The stock has a 36-month beta value of 1.26. Opinions on the stock are mixed, with 4 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for RGNX is 44.81M, and at present, short sellers hold a 10.73% of that float. On August 01, 2024, the average trading volume of RGNX was 551.29K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
RGNX) stock’s latest price update
Regenxbio Inc (NASDAQ: RGNX)’s stock price has dropped by -4.95 in relation to previous closing price of 14.25. Nevertheless, the company has seen a loss of -5.87% in its stock price over the last five trading days. prnewswire.com reported 2024-08-01 that Robust microdystrophin expression observed in new data from pivotal dose Patients aged 5.8 and 8.5 years at dosing had expression levels at 77.2% and 46.5% of control, respectively Consistent high expression of microdystrophin across treated patients in all age groups continues to support plans for accelerated approval Expects to initiate pivotal trial in Q4 2024 ROCKVILLE, Md., Aug. 1, 2024 /PRNewswire/ — REGENXBIO Inc. (Nasdaq: RGNX) today reported new, positive interim safety and efficacy data in the Phase I/II AFFINITY DUCHENNE® trial of RGX-202 in patients with Duchenne muscular dystrophy (Duchenne) ages 1 to 11 years old.
RGNX’s Market Performance
Regenxbio Inc (RGNX) has seen a -5.87% fall in stock performance for the week, with a 26.00% gain in the past month and a -16.39% plunge in the past quarter. The volatility ratio for the week is 8.21%, and the volatility levels for the past 30 days are at 6.91% for RGNX. The simple moving average for the past 20 days is 5.89% for RGNX’s stock, with a -18.12% simple moving average for the past 200 days.
Analysts’ Opinion of RGNX
Many brokerage firms have already submitted their reports for RGNX stocks, with Goldman repeating the rating for RGNX by listing it as a “Buy.” The predicted price for RGNX in the upcoming period, according to Goldman is $38 based on the research report published on June 07, 2024 of the current year 2024.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see RGNX reach a price target of $36. The rating they have provided for RGNX stocks is “Buy” according to the report published on March 11th, 2024.
RBC Capital Mkts gave a rating of “Outperform” to RGNX, setting the target price at $35 in the report published on March 08th of the current year.
RGNX Trading at 3.08% from the 50-Day Moving Average
After a stumble in the market that brought RGNX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -52.97% of loss for the given period.
Volatility was left at 6.91%, however, over the last 30 days, the volatility rate increased by 8.21%, as shares surge +24.21% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -15.31% lower at present.
During the last 5 trading sessions, RGNX fell by -6.60%, which changed the moving average for the period of 200-days by -16.47% in comparison to the 20-day moving average, which settled at $12.92. In addition, Regenxbio Inc saw -24.54% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at RGNX starting from CURRAN M SIMPSON, who proposed sale 25,106 shares at the price of $14.33 back on Jul 29 ’24. After this action, CURRAN M SIMPSON now owns shares of Regenxbio Inc, valued at $359,769 using the latest closing price.
KARABELAS ARGERIS N, the Director of Regenxbio Inc, sale 11,000 shares at $15.04 during a trade that took place back on Jul 29 ’24, which means that KARABELAS ARGERIS N is holding 11,286 shares at $165,495 based on the most recent closing price.
Stock Fundamentals for RGNX
Current profitability levels for the company are sitting at:
- -3.04 for the present operating margin
- 0.47 for the gross margin
The net margin for Regenxbio Inc stands at -3.0. The total capital return value is set at -0.51. Equity return is now at value -60.80, with -37.78 for asset returns.
Based on Regenxbio Inc (RGNX), the company’s capital structure generated 0.19 points at debt to capital in total, while cash flow to debt ratio is standing at -2.13. The debt to equity ratio resting at 0.23. The interest coverage ratio of the stock is -43.38.
Currently, EBITDA for the company is -250.81 million with net debt to EBITDA at -0.23. When we switch over and look at the enterprise to sales, we see a ratio of 8.32. The receivables turnover for the company is 5.01for trailing twelve months and the total asset turnover is 0.14. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.59.
Conclusion
To sum up, Regenxbio Inc (RGNX) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
